InsiderPulseNo transactions found.
| Date | Member | Chamber | Type | Amount |
|---|---|---|---|---|
| 2022-11-30 | Susie Lee(D-NV03) | house | Sale | $1,001 - $15,000 |
| 2021-01-05 | Susie Lee(D-NV03) | house | Sale | $1,001 - $15,000 |
| 2020-10-02 | Susie Lee(D-NV03) | house | Sale | $1,001 - $15,000 |
| 2020-05-27 | Susie Lee(D-NV03) | house | Sale | $1,001 - $15,000 |
| 2020-04-07 | Susie Lee(D-NV03) | house | Sale | $1,001 - $15,000 |
| Metric | FY2025 | FY2024 | FY2024 | FY2024 | FY2024 |
|---|---|---|---|---|---|
| Net sales | $2.58B+0.7% | $2.57B+295.0% | $649.7M+1.8% | $638.5M+4.5% | $610.8M |
| Cost of goods sold | $1.24B+4.7% | $1.19B-4.6% | $1.24B+0.8% | $1.23B | — |
| Gross profit | $1.34B-2.8% | $1.38B+287.4% | $355.9M+0.2% | $355.1M+9.0% | $325.9M |
| Selling, general and administrative expense | $844.3M+3.7% | $814.0M-3.3% | $841.7M+1.7% | $827.8M | — |
| Research and development expense | $275.6M-6.9% | $295.9M+19.6% | $247.4M-3.7% | $256.9M | — |
| Impairment of purchased intangibles and related items, net | $172.8M | $0 | — | — | — |
| Income from operations | $47.2M-82.5% | $269.0M-20.4% | $337.8M-30.0% | $482.6M | — |
| Interest expense | $49.0M+0.2% | $48.9M-1.0% | $49.4M+29.7% | $38.1M | — |
| Foreign currency exchange gains, net | -$6.6M-69.2% | -$3.9M+46.6% | -$7.3M-3550.0% | -$200K | — |
| (Gains) losses from change in fair market value of equity securities and loan receivable | -$900.4M-133.9% | $2.66B | — | — | — |
| Other income, net | -$90.3M+0.0% | -$90.3M+15.2% | -$106.5M-138.3% | -$44.7M | — |
| Net income (loss) before income taxes | $995.5M+142.5% | -$2.34B | — | — | — |
| (Provision for) benefit from income taxes | -$235.6M-147.3% | $498.3M | — | — | — |
| Net income (loss) | $759.9M+141.2% | -$1.84B | — | — | — |
| Net income (loss) per basic share (in dollars per share) | $27.9M+142.6% | -$65.4M-379.7% | $23.4M+130.6% | -$76.3M-666.6% | $13.5M |
| Weighted average common shares - basic (in shares) | $27.26B-3.4% | $28.21B-3.4% | $29.21B-1.9% | $29.79B | — |
| Net income (loss) per diluted share (in dollars per share) | $27.9M+142.6% | -$65.4M-380.0% | $23.3M+130.6% | -$76.3M-667.0% | $13.4M |
| Weighted average common shares - diluted (in shares) | $27.28B-3.3% | $28.21B-3.4% | $29.21B-1.9% | $29.79B | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
[Latest] Global Targeted DNA RNA Sequencing Market Size/Share Worth USD 46.9 Billion by 2035 at a 18.5% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
How The Biocon (NSEI:BIOCON) Story Is Shifting As Analysts Recut Growth And Risk Assumptions
Bio-Rad (BIO) Q2 2025 Earnings Call Transcript
Unlocking Bio-Rad (BIO) International Revenues: Trends, Surprises, and Prospects